Comparative Pharmacology
Head-to-head clinical analysis: VI DOM A versus VITAMIN A SOLUBILIZED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VI DOM A versus VITAMIN A SOLUBILIZED.
VI-DOM-A vs VITAMIN A SOLUBILIZED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinol binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription involved in cell growth, differentiation, and immune function.
Vitamin A (retinol) is essential for vision, immune function, and cellular differentiation. It binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), regulating gene transcription. In the retina, it forms rhodopsin, a light-sensitive pigment necessary for low-light vision.
1 mL intramuscular injection once weekly; each mL contains 100,000 IU vitamin A (as retinyl palmitate) and 50,000 IU vitamin D (as ergocalciferol).
Vitamin A solubilized: 10,000-50,000 IU orally once daily for deficiency. For severe deficiency: 100,000 IU intramuscularly once, repeated in 24 hours if needed. Maintenance: 10,000-20,000 IU orally daily.
None Documented
None Documented
The terminal elimination half-life of vitamin A is 10-12 hours for retinol, but due to hepatic storage and enterohepatic recirculation, the overall body half-life can extend to 2-3 weeks with chronic dosing.
Terminal half-life: 12.5–60 days (mean ~25 days) in adults; prolonged in hypervitaminosis A. Clinical context: Accumulation risk with chronic use due to slow elimination.
Vitamin A is primarily excreted via bile and feces as metabolites. Renal excretion accounts for less than 5% of an oral dose. Unchanged vitamin A is not significantly excreted in urine.
Renal: <1% as unchanged drug; biliary/fecal: >90% as metabolites and conjugated forms.
Category C
Category C
Vitamin A
Vitamin A